07 August 2026
07 August 2026
The molecular diagnostics company's concurrent CLIA Waiver by Application, if granted, would allow testing in decentralised point-of-care settings.
The ongoing multicentre, open-label study focuses on examining the safety, tolerability, and preliminary efficacy of DISP-10.
The partnership gives Ono the exclusive option to license worldwide rights to develop the therapeutic programmes.
Alteogen is set to receive an upfront payment and could earn additional amounts through development, regulatory, and sales milestone payments.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
